266 related articles for article (PubMed ID: 9618394)
1. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
[TBL] [Abstract][Full Text] [Related]
2. Single-point plasma or urine dextromethorphan method for determining CYP3A activity.
Kuo BP; Hu OY; Hsiong CH; Pao LH; Chen TS; Hung CF
Biopharm Drug Dispos; 2003 Dec; 24(9):367-73. PubMed ID: 14689465
[TBL] [Abstract][Full Text] [Related]
3. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
[TBL] [Abstract][Full Text] [Related]
4. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
[TBL] [Abstract][Full Text] [Related]
6. Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.
Chen R; Wang H; Shi J; Hu P
Int J Clin Pharmacol Ther; 2016 May; 54(5):330-6. PubMed ID: 26902503
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
8. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration.
Corado CR; McKemie DS; Knych HK
Drug Test Anal; 2017 Jun; 9(6):880-887. PubMed ID: 27580591
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
[TBL] [Abstract][Full Text] [Related]
11. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children.
Kennedy MJ; Abdel-Rahman SM; Kashuba AD; Leeder JS
J Clin Pharmacol; 2004 Jul; 44(7):708-14. PubMed ID: 15199075
[TBL] [Abstract][Full Text] [Related]
12. LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation.
Lutz U; Völkel W; Lutz RW; Lutz WK
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):217-25. PubMed ID: 15556536
[TBL] [Abstract][Full Text] [Related]
13. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
14. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of dextromethorphan in human liver microsomes: a rapid HPCL assay to monitor cytochrome P450 2D6 activity.
Vielnascher E; Spatzenegger M; Mayrhofer A; Klinger P; Jäger W
Pharmazie; 1996 Aug; 51(8):586-8. PubMed ID: 8794469
[TBL] [Abstract][Full Text] [Related]
17. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
18. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.
Basci NE; Bozkurt A; Kayaalp SO; Sayal A; Isimer A
Eur J Drug Metab Pharmacokinet; 1998; 23(1):1-5. PubMed ID: 9625265
[TBL] [Abstract][Full Text] [Related]
19. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
[TBL] [Abstract][Full Text] [Related]
20. Salivary analysis for determination of dextromethorphan metabolic phenotype.
Hou ZY; Pickle LW; Meyer PS; Woosley RL
Clin Pharmacol Ther; 1991 Apr; 49(4):410-9. PubMed ID: 2015730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]